Overview

• Among 110 men with obesity or type 2 diabetes, 18 months of semaglutide, dulaglutide or tirzepatide treatment produced an average 10% weight loss and increased the share with normal testosterone from 53% to 77%.
• Investigators attribute the hormonal improvement to enhanced insulin sensitivity, reduced inflammation and lower aromatase activity linked to fat reduction.
• The study’s retrospective design and lack of hormone measurements after therapy discontinuation prevent firm conclusions about causality or long-term durability.
• Common side effects reported include nausea, vomiting and diarrhea, while rare but serious risks involve pancreatitis, vision changes and gastroparesis.
• If confirmed by controlled prospective trials, these findings could lead clinicians to adjust hormone therapy dosing and view GLP-1s as a noninvasive alternative for addressing low testosterone.